Literature DB >> 12536317

Minimally invasive (encapsulated) follicular carcinoma of the thyroid gland is the low-risk counterpart of widely invasive follicular carcinoma but not of insular carcinoma.

Paola Collini1, Giuseppe Sampietro, Juan Rosai, Silvana Pilotti.   

Abstract

Minimally invasive (encapsulated) follicular carcinoma (MIFC), widely invasive follicular carcinoma (WIFC), and insular carcinoma (IC) are three distinct types of thyroid carcinomas composed of follicular cells, IC representing the poorly differentiated counterpart. Our aim was to test whether there is a time-dependent relationship among these three entities, in particular whether MIFC is the low-risk form of the entire group. We used overall survival analysis and multiple correspondence analysis (MCA), the latter exploring the clinicopathological characteristics at onset (sex, age, TNM/pTNM classification). The study included 18 MIFCs, 29 WIFCs, and 27 ICs. On the basis of both overall survival and MCA, WIFC emerged as the high-risk counterpart of MIFC, occurring in older age, with a larger size, a widespread growth into the thyroid parenchyma, and presenting with distant metastases. In both types of follicular carcinoma distant metastases involved only lung and bone, and there was no tendency for local spread beyond the thyroid capsule or nodal metastases. By contrast, IC confirmed to be a distinct high-risk lesion, showing both follicular and papillary-related biological behavior characteristics.

Entities:  

Mesh:

Year:  2002        PMID: 12536317     DOI: 10.1007/s00428-002-0701-2

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  15 in total

Review 1.  Follicular-patterned tumors of the thyroid: the battle of benign vs. malignant vs. so-called uncertain.

Authors:  Virginia A LiVolsi; Zubair W Baloch
Journal:  Endocr Pathol       Date:  2011-12       Impact factor: 3.943

Review 2.  Our approach to follicular-patterned lesions of the thyroid.

Authors:  Zubair W Baloch; Virginia A LiVolsi
Journal:  J Clin Pathol       Date:  2006-06-23       Impact factor: 3.411

Review 3.  Handling of thyroid follicular patterned lesions.

Authors:  Juan Rosai
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

4.  Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons.

Authors:  Hiroshi Takami; Yasuhiro Ito; Takahiro Okamoto; Akira Yoshida
Journal:  World J Surg       Date:  2011-01       Impact factor: 3.352

5.  Follicular adenoma and carcinoma of the thyroid gland.

Authors:  Christopher R McHenry; Roy Phitayakorn
Journal:  Oncologist       Date:  2011-04-11

Review 6.  Crucial parameters in thyroid carcinoma reporting - challenges, controversies and clinical implications.

Authors:  Bin Xu; Ronald A Ghossein
Journal:  Histopathology       Date:  2018-01       Impact factor: 5.087

Review 7.  [Minimally invasive follicular thyroid carcinoma : Not always total thyroidectomy].

Authors:  M Hermann; K Tonninger; F Kober; E-M Furtlehner; A Schultheis; N Neuhold
Journal:  Chirurg       Date:  2010-07       Impact factor: 0.955

Review 8.  [Lymph node and distant metastases of thyroid gland cancer. Metastases in the thyroid glands].

Authors:  K W Schmid
Journal:  Pathologe       Date:  2015-11       Impact factor: 1.011

Review 9.  Follicular-patterned afflictions of the thyroid gland: reappraisal of the most discussed entity in endocrine pathology.

Authors:  Zubair W Baloch; Virginia A LiVolsi
Journal:  Endocr Pathol       Date:  2014-03       Impact factor: 3.943

10.  Minimally invasive follicular thyroid cancer (MIFTC)--a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Gianlorenzo Dionigi; Jean-Louis Kraimps; Kurt Werner Schmid; Michael Hermann; Sien-Yi Sheu-Grabellus; Pierre De Wailly; Anthony Beaulieu; Maria Laura Tanda; Fausto Sessa
Journal:  Langenbecks Arch Surg       Date:  2014-02       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.